BioDelivery Sciences International, Inc. (NASDAQ:BDSI) – Investment analysts at Cantor Fitzgerald reduced their FY2018 earnings estimates for shares of BioDelivery Sciences International in a research report issued to clients and investors on Sunday. Cantor Fitzgerald analyst L. Chen now forecasts that the specialty pharmaceutical company will post earnings of ($0.60) per share for the year, down from their previous forecast of ($0.53). Cantor Fitzgerald has a “Buy” rating and a $5.00 price objective on the stock.
A number of other equities analysts have also issued reports on the company. Piper Jaffray Companies set a $4.00 target price on BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Sunday, October 22nd. Janney Montgomery Scott increased their price target on BioDelivery Sciences International from $3.00 to $4.00 and gave the stock a “fair value” rating in a research report on Monday, July 24th. HC Wainwright initiated coverage on BioDelivery Sciences International in a research report on Sunday, September 10th. They set a “buy” rating and a $5.00 price target on the stock. Roth Capital set a $5.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Thursday, October 12th. Finally, ValuEngine downgraded BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. BioDelivery Sciences International has an average rating of “Buy” and an average price target of $4.29.
WARNING: “Cantor Fitzgerald Analysts Lower Earnings Estimates for BioDelivery Sciences International, Inc. (BDSI)” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://stocknewstimes.com/2017/11/15/cantor-fitzgerald-analysts-lower-earnings-estimates-for-biodelivery-sciences-international-inc-bdsi.html.
Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded down $0.15 during mid-day trading on Wednesday, reaching $2.28. The company had a trading volume of 523,590 shares, compared to its average volume of 533,005. The company has a quick ratio of 1.07, a current ratio of 1.28 and a debt-to-equity ratio of 1.89. BioDelivery Sciences International has a one year low of $1.50 and a one year high of $3.60.
BioDelivery Sciences International (NASDAQ:BDSI) last issued its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01. The company had revenue of $11.25 million during the quarter, compared to analyst estimates of $9.40 million. BioDelivery Sciences International had a return on equity of 33.83% and a net margin of 10.40%. The firm’s quarterly revenue was up 215.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.30) EPS.
In other news, CEO Mark A. Sirgo sold 50,000 shares of the firm’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $2.95, for a total transaction of $147,500.00. Following the sale, the chief executive officer now directly owns 1,509,262 shares in the company, valued at approximately $4,452,322.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Mark A. Sirgo sold 24,516 shares of the firm’s stock in a transaction dated Tuesday, September 19th. The shares were sold at an average price of $2.75, for a total value of $67,419.00. Following the sale, the chief executive officer now owns 1,509,262 shares in the company, valued at $4,150,470.50. The disclosure for this sale can be found here. Insiders have sold a total of 402,127 shares of company stock worth $1,142,798 over the last 90 days. Insiders own 7.73% of the company’s stock.
Large investors have recently bought and sold shares of the company. Wells Fargo & Company MN grew its position in shares of BioDelivery Sciences International by 138.2% during the 3rd quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock valued at $105,000 after acquiring an additional 20,599 shares during the period. Valley National Advisers Inc. lifted its stake in BioDelivery Sciences International by 59.0% in the 2nd quarter. Valley National Advisers Inc. now owns 37,715 shares of the specialty pharmaceutical company’s stock valued at $106,000 after buying an additional 14,000 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in BioDelivery Sciences International in the 3rd quarter valued at about $116,000. Cutter & CO Brokerage Inc. lifted its stake in BioDelivery Sciences International by 2.4% in the 2nd quarter. Cutter & CO Brokerage Inc. now owns 43,430 shares of the specialty pharmaceutical company’s stock valued at $122,000 after buying an additional 1,000 shares in the last quarter. Finally, Advisor Group Inc. lifted its stake in BioDelivery Sciences International by 42.1% in the 2nd quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock valued at $126,000 after buying an additional 13,341 shares in the last quarter. Hedge funds and other institutional investors own 40.68% of the company’s stock.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.